We’re thrilled to share several exciting developments from the third quarter of 2025, including the arrival of a new addition to our commercial product portfolio – Talicia®, a leading triple therapy for the treatment of Helicobacter pylori infections: Talicia features include three key advantages – high eradication rates at >90%,

We enjoyed a strong first half of the year! During the second quarter, our momentum continued, as we advanced our mission of working together to deliver favorable commercial and clinical development results. During the quarter we remained dedicated to advancing our mission of working together to provide unique products that

Our approved brands remain a key driver of performance, while expanded international partnerships and steady advancement in our clinical development programs further strengthen our position. We are also evaluating select acquisition opportunities that align with our strategic objectives. As we look ahead, we remain committed to executing our growth strategy